對Piperacillin具有感受性，以及對Piperacillin具抗藥性但對Piperacillin/Tazobactam有感受性之β-lactamase產生菌株所引起之中至嚴重程度感染。

Antibiotic, Penicillin

Distribution: Well into lungs, intestinal mucosa, uterus, ovary, fallopian tube, interstitial fluid, gallbladder, and bile; penetration into CSF is low in subjects with noninflamed meninges; Vd: Piperacillin: Adolescents and Adults: 0.243 L/kg.
Protein binding: Piperacillin: ~26% to 33%; Tazobactam: 31% to 32%.
Metabolism: Piperacillin: 6% to 9% to desethyl metabolite (weak activity); Tazobactam: ~22% to inactive metabolite.
Half-life elimination: Piperacillin: Adults: 0.7 to 1.2 hours.
Metabolite: 1 to 1.5 hours.
Time to peak, plasma: Immediately following completion of 30-minute infusion.
Excretion: Clearance of both piperacillin and tazobactam are directly proportional to renal function; Piperacillin: Urine (68% as unchanged drug); feces (10% to 20%); Tazobactam: Urine (80% as unchanged drug; remainder as inactive metabolite).

Hypersensitivity to penicillins, cephalosporins, beta-lactamase inhibitors, or any component of the formulation.

B; Piperacillin/tazobactam is considered compatible with pregnancy when used for the treatment airway diseases, such as cystic fibrosis, in pregnant women.

Piperacillin is present in breast milk.

>10%: diarrhea (11%).
1% to 10%: flushing (≤1%), hypotension (≤1%), phlebitis (1%), thrombophlebitis (≤1%), pruritus (3%), skin rash (4%), hypoglycemia (≤1%), abdominal pain (1%), clostridioides difficile colitis (≤1%), constipation (8%), dyspepsia (3%), nausea (7%), vomiting (3%), purpuric disease (≤1%), anaphylaxis (≤1%), candidiasis (2%), injection-site reaction (≤1%), headache (8%), insomnia (7%), rigors (≤1%), arthralgia (≤1%), myalgia (≤1%), epistaxis (≤1%), fever (2%).

1. Bite wound infection, treatment (animal or human bite) (off-label use): IV: 3.375 g every 6 to 8 hours for 5 to 14 days.
2. Bloodstream infection (gram-negative bacteremia) (off-label use): Community-acquired infection, immunocompetent host: IV: 3.375 g every 6 hours for 7 to 14 days; Health care-associated infection, including catheter-related, immunosuppressed host, or for coverage of P. aeruginosa: IV: 4.5 g every 6 hours for 7 to 14 days.
3. Cystic fibrosis, severe acute pulmonary exacerbation or failure of oral therapy, for coverage of P. aeruginosa (off-label use): IV: 4.5 g every 6 hours for 10 to 14 days.
4. Diabetic foot infection, moderate to severe: IV:3.375 g every 6 hours or 4.5 g every 8 hours for 2 to 4 weeks.
5. Intra-abdominal infection: Cholecystitis, acute: IV: 3.375 g or 4.5 g every 6 hours; Other intra-abdominal infection (eg, cholangitis, perforated appendix, diverticulitis, intra-abdominal abscess): IV: 3.375 g or 4.5 g every 6 hours for 4 to 5 days.
6. Malignant (necrotizing) external otitis, hospitalized patients (alternative agent) (off-label use): IV: 4.5 g every 6 hours for 6 to 8 weeks.
7. Neutropenic fever, high-risk patients with cancer (empiric therapy) (off-label use): IV: 4.5 g every 6 to 8 hours.
8. Pneumonia: Community-acquired pneumonia: IV: 4.5 g every 6 hours for at least 5 days; Hospital-acquired or ventilator-associated pneumonia: IV: 4.5 g every 6 hours for 7 days.
9. Sepsis and septic shock (broad-spectrum empiric therapy, including P. aeruginosa) (off-label use): IV: 4.5 g every 6 hours.
10. Skin and soft tissue infection, moderate to severe: IV: 3.375 g every 6 hours or 4.5 g every 8 hours for 5 to 14 days.
11. Urinary tract infection, complicated (pyelonephritis or urinary tract infection with systemic signs/symptoms) (off-label use): IV: 3.375 g every 6 hours for 5 to 14 days.

No dosage adjustment necessary.